Albireo Pharma, Inc. announced the appointments of two scientific leaders, Drs. Paul Streck and Craig Hopkinson, to the Enterprise Leadership Team and Board of Directors, respectively. These appointments coincide with an important time for Albireo as the Company continues to deliver on clinical, regulatory, and commercialization milestones for Bylvay® (odevixibat) for indications potentially across three pediatric cholestatic liver diseases while advancing investigational compounds for adult liver and viral diseases. As the Chief Medical Officer, Dr. Streck will join the Albireo Enterprise Leadership Team and will be responsible for providing vision, leadership, and expertise for the Company's next growth phase, necessary to shape and enhance the CMO organization within a fully realized biopharmaceutical company.

Dr. Streck, age 59, has more than 25 years of experience in drug development, regulatory and medical affairs leadership. He has served as Chief Medical Officer of Arena Pharmaceuticals, Inc., from November 2020 through its acquisition by Pfizer Inc. in March 2022 and thereafter at Pfizer until December 2022. Prior to that, Dr. Streck served as Chief Medical Officer of Alder Biopharmaceuticals, Inc., from January 2019 to February 2020, and as Chief Medical Officer of Insmed Incorporated, from April 2017 to January 2019.

Before joining Insmed, Dr. Streck served as Vice President, Global Medical Specialty Franchise, Immuno-inflammation at GlaxoSmithKline from November 2015 to March 2017, where he was responsible for portfolio strategy, including drug launch, life cycle management, post-registration clinical strategy and health economics. From November 2007 to November 2015, Dr. Streck held various positions at Shire Pharmaceuticals, which was acquired by Takeda Pharmaceutical Company in January 2019. Dr. Streck served as Group Vice President, Clinical Development/TA Lead (Hematology, Gastrointestinal, Internal Medicine) at Shire Pharmaceuticals from November 2013 to November 2015.

Prior to that, Dr. Streck served as Global Head of Medical Affairs, Internal Medicine (November 2012 to December 2013), Product General Manager, Emerging Business Unit (November 2011 to November 2012), and Senior Director, Global Clinical Development (November 2007 to December 2012). From February 2006 to October 2007, Dr. Streck was Director of Marketing at AMGEN USA Inc. Dr. Streck holds a M.B.A. from the Duke University Fuqua School of Business, a M.D. from Jefferson Medical College, a D.M.D. from the Temple University School of Dentistry, and a B.A. in chemistry from Rutgers University. Dr. Streck will join the Company on December 19, 2022.

Dr. Hopkinson, age 54, has served as Executive Vice President, Research and Development and Chief Medical Officer of Alkermes PLC, since January 2020. Dr. Hopkinson has more than 25 years of experience building and leading clinical development organizations and medical affairs groups. Prior to assuming these positions, Dr. Hopkinson was the Chief Medical Officer and Senior Vice President of Medicines Development and Medical Affairs of Alkermes, Inc. from February 2018 to January 2020, and Chief Medical Officer and Senior Vice President of Clinical Development and Medical Affairs of Alkermes, Inc. from May 2017 to February 2018.

Before joining Alkermes, Inc., Dr. Hopkinson served as Senior Vice President of Clinical Development and Head of Global Medical Affairs at Vertex Pharmaceuticals Incorporated, from July 2014 until May 2017. Prior to that, Dr. Hopkinson held various executive management positions at Eisai Pharmaceuticals, including President of the Eisai Value Maximization Systems from January 2013 to July 2014 and President and Chief Medical Officer of the Frontier Product Creation Unit from October 2011 to December 2012. Dr. Hopkinson holds a Bachelor of Medicine and a Bachelor of Surgery from the University of the Orange Free State in South Africa.

The Board has concluded that Dr. Hopkinson's qualifications to serve on the Board include his executive leadership experience and his extensive experience in research and development, medical affairs, and interactions with the U.S. Food and Drug Administration.